Table 2 Compounds that have been shown to inhibit SFTSV infectiona.
Compound | Model | Effective dose | Reference |
|---|---|---|---|
Ribavirin | Case studies | Case studies show varying results | |
2’-Fluoro-2’-deoxycytidine | IFNAR−/− mice | 3.7 ± 2.0 µM | |
Lovastatin | SW13 cells | 20 µM | |
Fenofibrate | SW13 cells | 20 µg/mL | |
Caffeic acid | HUH7.5 cells | 48 µM | |
Amodiaquine | Vero cells | 19.1 ± 5.1 µM | |
Favipiravir | Cell culture, animal models, and clinical trials | Clinical trials in progress | |
Haxachlorophene | Vero and HUH7 cells | IC50: 1.3 ± 0.3 | |
Triclosan | Vero and HUH7 cells | IC50: 3.2 ± 0.4 | |
Regorafenib | Vero and HUH7 cells | IC50: 4.5 ± 0.5 | |
Eltrombopag | Vero and HUH7 cells | IC50: 4.1 ± 0.2 | |
Broxyquinoline | Vero and HUH7 cells | IC50: 5.8 ± 1.3 | |
Arginine | Case studies | Requires further study | |
Interferon | Case studies | Requires further study | |
N-Butyldeoxynojirimycin-HCL | A549 cells | ~50 µM | |
Nifedipine | Cell culture, animal models, case studies | Varies in patients |
